# Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

> **NCT01732107** · PHASE2 · TERMINATED · sponsor: **Noah Hahn, M.D.** · enrollment: 13 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Dovitinib

## Key facts

- **NCT ID:** NCT01732107
- **Lead sponsor:** Noah Hahn, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2017-03-06
- **Final completion:** 2017-03-06
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Development of dovitinib was stopped.
- **Last updated:** 2022-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732107, "Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01732107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*